Compositions and methods for enhancing sexual pleasure and performance

ABSTRACT

Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis, including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.

CROSS REFERENCE TO RELATED APPLICATION

This Application is a continuation-in-part of U.S. patent applicationSer. No. 16/056,726, filed Aug. 7, 2018, now issued U.S. Pat. No.10,220,063, which is a continuation-in-part of U.S. patent applicationSer. No. 14/538,527, filed Nov. 11, 2014, now issued U.S. Pat. No.10,064,905, which claims the benefit of U.S. Prov. App. Ser. No.61/902,501, filed Nov. 11, 2013, the disclosures of which areincorporated herein by reference in their entirety

BACKGROUND OF THE INVENTION 1. Field of the Invention

The invention is in the field of pharmaceutical preparations,particularly for sexual enhancement in men, women, the disabled, and theaged.

2. Relevant Technology

There are a variety of health issues that can impact the ability ordesire to engage in intimate sexual relations, which form a healthy partof adult relationships. These include sexual dysfunction in men andwomen and a loss of sensitivity and pleasure. The inability to performand/or lack of desire to engage in sexual relations can detrimentallyimpact a relationship and can lead to divorce, breakup, or long-termboredom. It can lead to loss of self-esteem or even mental illness.

Men are more likely than women to have threshold desire to have sex,which is both a physical and psychological need, and are therefore morelikely to initiate sex with a partner. When a man is extremely stressed,anxious or insecure, however, his ability to perform can also beinhibited physically (temporary erectile dysfunction). Older or sick mencan suffer chronic erectile dysfunction (“ED”), which can be completelyincapacitating relative to ability to perform. Particularly as men ageand/or if suffering from chronic illness, they can experience lack ofthreshold desire, loss of sensitivity, loss of pleasure (collectively“arousal disorder”) and/or difficulty in climaxing (“orgasmicdisorder”). At the opposite end of the spectrum is premature ejaculationwhich can severely curtail duration and satisfaction for bothparticipants.

In women, sexual dysfunction is more complex and difficult to define butcan involve lack of threshold desire, loss of sensitivity, loss ofpleasure (collectively “sexual arousal disorder”) and/or inability toclimax (“orgasmic disorder”). Emotional and psychological sexualdysfunction may be more common among women. There are many studies thatshow that women commonly have insecurities about body image and carrytheir stresses and anxieties of life with them into the bedroom. Theseinsecurities and stresses greatly impact the mood-factor (emotional andpsychological state) and inhibit physiological arousal, such asdecreased blood flow to the clitoris and labia, often making orgasmunattainable.

Compared to men, women have more complex emotions that can be barriersto threshold desire. Women are more sensitive sexually to insecurities,stresses, and anxieties than men. Books and commentators have been knownto say: “sex is much more emotional for women than men.” Also, men oftenview sex as a way to release and reduce stress and tension. In contrast,women often identify sex with increased stress and anxiety, particularlywomen who both work outside the home and raise children. Examples ofhypothetical stresses include: “I'm not in the mood.” “I'm stressed ortired from work, the kids, play dates, managing the household, dirtydishes.” “Really? We're doing this now, etc.?” So, sex can becomesanother item on an already stressful checklist. Examples of hypotheticalanxieties include: “I think I've put on a few pounds.” “My butt doesn'tlook good.” “I feel bloated and hormonal.” “How do I compare?” “Will Ibe able to perform for my partner, act sufficiently interested, beinterested, etc.?”

While there are drugs (e.g., Viagra®, Cialis® and Levitra®, known asphosphodiesterase type 5 (PDE5) inhibitors) that can remedy thephysiological condition of ED and permit men to perform sexually, theygenerally do not restore lost sensitivity, diminished enjoyment, ordifficulty in climaxing. Such drugs are generally ineffective for womenbecause they do not adequately address issues involving lack ofthreshold desire, loss of sensitivity, loss of pleasure, or inability toclimax (i.e., because they do virtually nothing to address powerfulpsychological forces affecting women).

In fact, the main reason physiological enhancers for women on the markettoday do not work is because they fail to address the mood-factor.Unlike men, who feel buildup of semen and equate it with sexual tensionand need to find sexual release, the trigger for women to desire sex istypically not physical but psychological and strongly correlated withmood and self-image. Their emotional and psychological state canactually dictate physiological response, arousal and performancesignificantly more than in men. And while men are notorious finishersduring sex, women are not so prone (50% reportedly never achievingorgasm during sex). This is generally not due to a lack of physicalstimulation but rather emotional barriers or inhibitions. Only enhancingthe physiological response in women does not adequately address theinability to reach climax.

Many of the foregoing problems are particularly acute in men and womenwho suffer from physical ailments and/or age-related conditions thatcause sexual dysfunction and/or lack of desire and enjoyment. Again, itmust be emphasized that performance does not necessarily coincide withnormal enjoyment of sexual relations. Drugs that only address lack ofperformance but fail to address diminished desire, sensitivity, andpleasure are incomplete solutions.

While there are herbal supplements that purport to address some or allof the foregoing issues, there remains a long-felt but unmet need tofind compositions that effectively and reliably addresses diminishedperformance while also increasing desire, sensitivity and enjoyment.

SUMMARY

The present invention relates to pharmaceutical preparations and relatedmethods of manufacture and use for enhancing various aspects of sexualactivity, and treating sexual dysfunction in men and women. Toaccomplish these results the pharmaceutical preparations include acombination of: (1) one or more cannabinoid compounds derived from theplant genus Cannabis, which are included in an effective amount and/orin a ratio effective to enhance sexual pleasure (e.g., threshold desire,sensitivity and/or enjoyment); and (2) one or more compounds thatenhance blood flow to the genital region in order to enhance sexualresponse (e.g., ability to perform and/or time to arousal). Thecombination results in increased ability to perform and enjoyment ofintimate sexual activities by men and women, which treats one or more ofarousal disorder, orgasmic disorder, and erectile dysfunction in bothmales and females.

According to several embodiments, the pharmaceutical preparations can bedelivered in a manner so that the time of enhanced sexual response andsexual pleasure coincide or complement each other (i.e., so that bothare present at the same time at least some of the time). Methods ofdelivery include oral delivery, topical delivery, injection, inhalation,or combinations thereof. Advantageously, the components of thepharmaceutical preparations can be delivered together in a single modeof delivery for simplicity and proper dosage (e.g., in a combined oralpreparation or a topical preparation). Alternatively, the components ofthe pharmaceutical preparations can be pre-packaged in a kit anddelivered individually, whether simultaneously or sequentially.

According to several embodiments, the one or more cannabinoid compoundsderived from the plant genus Cannabis include at least two cannabinoidcompounds that are included in amounts and/or ratios in order to addressa particular condition being treated. By way of example, it has beenfound that persons (men or women) suffering from lack of thresholddesire, sensitivity, pleasure and/or ability to climax can benefit frompreparations that have a relatively higher quantity or ratio oftetrahydrocannabinol (THC) as compared to cannabidiol (CBD) (e.g., morethan 2:1 THC/CBD). Alternatively, persons suffering from prematureejaculation (men) or who are prone to nervousness or anxiety whenengaging in sexual activity (men or women) can benefit from preparationsthat have a relatively lower quantity THC/CBD ratio (e.g., less than0.5:1 THC/CBD). Persons with normal sexual response can benefit from anintermediate THC/CBD ratio (e.g., between 0.5:1 to 2:1 THC/CBD).

As discussed above, women can have very real insecurities about bodyimage and carry stresses and anxieties into the bedroom. Similarly, whena man is extremely stressed, anxious or insecure, his ability to performsexually can also be inhibited. Insecurities and stresses can greatlyimpact emotional and psychological state and inhibit physiologicalarousal, often making sex impossible for the man and/or orgasmunattainable for the woman. However, by addressing both the mood-factor(emotional and psychological state) and blood flow to the genitalia,physical arousal occurs easier and more naturally, which permitsawareness and focus to shift to sensuality, sexual sensitivity, andsexual stimulation, enhancing sexual pleasure for both men and women,and promoting orgasms and sometimes multiple orgasms.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Disclosed herein are pharmaceutical preparations that include at leastone compound that enhances sexual pleasure and at least one othercompound that enhances sexual response. Also disclosed are methods ofmanufacturing and using such pharmaceutical preparations.

The term “sexual pleasure” can include a variety of physiological and/orpsychological aspects or conditions that affect the amount of enjoymentof sexual activity. Examples include, but are not limited to, thresholddesire to commence sexual activity, physical sensitivity during sexualactivity, psychological pleasure or awareness during sexual activity,ability to reach climax, amount of pleasure leading up to climax,quality of climax, duration of climax, and the like.

The term “sexual response” can include a variety of physiological and/orpsychological aspects that affect the ability to perform sexualactivities. In men, the most common condition is the inability toachieve or maintain an erection. In women, conditions that inhibitsexual response are more varied and complex but include, for example,inability or delay in becoming aroused while being kissed or touched inerogenous zones. In many cases such inability can be more psychologicalthan physiological.

The term “sexual arousal disorder” can apply to men and women and iswhere a person has difficulty with arousal or are unable to becomearoused or maintain arousal during sexual activity.

The term “orgasmic disorder” can apply to men and women and is where aperson has persistent or recurrent difficulty in achieving orgasm aftersufficient sexual arousal and ongoing stimulation.

The term “low sexual desire” can apply to men and women and is where theperson has lack of sexual interest and willingness to be sexual.

According to several embodiments, the one or more compounds that enhancesexual pleasure (“pleasure-enhancing component”) include one or morecannabinoid compounds from the plant genus Cannabis. Examples ofcannabinoid compounds include tetrahydrocannabinol (“THC”), which is asubgenus of several different isomers having different chiral centersand is the main psychoactive constituent of Cannabis; cannabidiol(“CBD”), which is less or perhaps even non-psychoactive but may modulatecertain effects of THC in the nervous system, cannabinol (“CBN”),tetrahydrocannabivarin (“THCV”), and cannabigerol (“CBG”). Examples ofsynthesized cannabinoid compounds include dronabinol (Marinol) (a pureisomer of THC, (−)-trans-Δ9-tetrahydrocannabinol, which is the mainisomer found in cannabis) and nabilone (a synthetic racemic mixtureconsisting of the (S,S) and the (R,R) isomers of THC). Synthetic formsof THC and CBD can function the same as plant-based THC and CBD,respectively, and are therefore “cannabis extracts” unless expresslyexcluded.

Without being bound to any particular theory, it is postulated thatpharmaceutical preparations that have higher quantities of THC have amore excitatory effect on the central nervous system whilepharmaceutical preparations that have lower quantities of THC and/orhigher quantities of CBD can have a more calming effect. Selecting theoptimal combination of excitatory and calming effects can beadvantageous in treating a particular sexual dysfunction.

In some embodiments, optimal results can be achieved when thepharmaceutical preparation includes at least two cannabinoid compoundsthat are included in amounts and/or ratios in order to address aparticular condition being treated. It should be understood thatCannabis plants typically have dozens of cannabinoids and that theTHC/CBD ratios expressed herein may work best when a substantialquantity (e.g., most or all) of the minor cannabinoid compounds found inCannabis plants are included. In fact, the THC/CBD ratios may, in atleast some cases, be a proxy for the ratio of other cannabinoidcompounds found in a particular Cannabis species. Thus, the term“consisting essentially of” does not exclude any of the minorcannabinoid compounds—any or all may be present—so long as they do notdeactivate or so substantially alter the effects of TCH and/or CBD thatit/they can no longer be recognized.

By way of illustration, it has been found that persons (men or women)suffering from lack of threshold desire, sensitivity, pleasure and/orability to climax (arousal disorder and/or orgasmic disorder) canbenefit from preparations that have a relatively higher quantity orratio of tetrahydrocannabinol (THC) as compared to cannabidiol (CBD).Such preparations may be euphemistically called “high excitementpreparations” or “amplifying preparations”. Amplifying preparations may,in some cases, include THC and no CBD.

Alternatively, persons suffering from premature ejaculation (men) or whoare prone to nervousness or anxiety when engaging in sexual activity(men or women) can benefit from preparations that have a relativelylower quantity or ratio of THC as compared to CBD (or higher ratio ofCBD to THC). Such preparations may be euphemistically called “calmingpreparations” or “stabilizing preparations”. Calming preparations may,in some cases, include CBD and no THC.

In yet other cases, people who do not suffer from any particularcondition but nevertheless wish to enhance sexual experience can benefitfrom preparations that have a balanced quantity or ratio of THC ascompared to CBD. Such preparations may be euphemistically called“intermediate preparations” or “balanced preparations”. Suchpreparations will typically include both THC and CBD.

According to several embodiments, the quantity of THC in amplifyingpreparations can be in a range of about 50 mg to about 500 mg per dose,or about 75 mg to about 400 mg per dose, or about 100 mg to about 300 mgper dose. To complement the THC, the quantity of CBD in amplifyingpreparations can be in a range of about 10 mg to about 250 mg per dose,or about 15 mg to about 200 mg per dose, or about 25 mg to about 150 mgper dose. The ratio of THC to CDB in amplifying preparations can be atleast about 2:1 THC/CBD, or in a range of about 2:1 to about 25:1THC/CBD, or about 3:1 to about 20:1 THC/CBD, or about 4:1 to about 15:1THC/CBD.

According to several embodiments, the quantity of THC in stabilizingpreparations can be in a range of about 10 mg to about 250 mg per dose,or about 15 mg to about 200 mg per dose, or about 25 mg to about 150 mgper dose. To complement the THC, the quantity of CBD in stabilizingpreparations can be in a range of about 50 mg to about 500 mg per dose,or about 75 mg to about 400 mg per dose, or about 100 mg to about 300 mgper dose. The ratio of THC to CDB in stabilizing preparations can beless than or equal to about 0.5:1 THC/CBD. Stated another way, the ratioof CBD to THC can be at least about 2:1 CBD/THC, or in a range of about0.5:1 to about 25:1 CBD/THC, or about 3:1 to about 20:1 CBD/THC, orabout 4:1 to about 15:1 CBD/THC.

According to several embodiments, the quantity of THC in balancedpreparations can be in a range of about 25 mg to about 400 mg per dose,or about 50 mg to about 300 mg per dose, or about 75 mg to about 250 mgper dose. To complement the THC, the quantity of CBD in balancedpreparations can be in a range of 25 mg to about 400 mg per dose, orabout 50 mg to about 300 mg per dose, or about 75 mg to about 250 mg perdose. The ratio of THC to CDB in balanced preparations can be in a rangeof about 0.1:1 to about 10:1 THC/CBD, or about 0.25:1 to about 5:1THC/CBD, or about 0.5:1 to about 2:1 THC/CBD.

While pharmaceutical preparations can fall within the meaning of anamplifying preparation, stabilizing preparation, or balancedpreparation, it will be understood that these are merely euphemistic orarbitrary categories created for the purpose of teaching generalprinciples regarding how to manufacture a preparation designed to treatone or more particular conditions. Nevertheless, preparations mayinclude amounts and/or ratios of cannabinoid compounds in order to havea desired balance between excitement and stabilization. In many casesthe preparations may be formulated to both excite and stabilize. Therelative degrees of excitement and stabilization can be selected for aspecific condition or gender.

In view of this, compositions containing THC, alone or in combinationwith CBD, may include THC in a range of about 10 mg to about 500 mg perdose, or about 15 mg to about 400 mg per dose, or about 25 mg to about300 mg per dose, or about 50 mg to about 250 mg per dose, or about 75 mgto about 150 mg per dose. The amount of THC can be at least 5 mg, 7.5mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 50 mg, 60 mg, 75mg, or 100 mg (lower values) and up to 750 mg, 500 mg, 450 mg, 400 mg,350 mg, 300 mg, 250 mg, 200 mg, 175 mg, 150 mg, 120 mg, or 100 mg (uppervalues) of THC per dose, and a ranges bounded by a lower and uppervalue.

Similarly, compositions containing CBD, alone or in combination withTHC, may include CBD in a range of about 10 mg to about 500 mg per dose,or about 15 mg to about 400 mg per dose, or about 25 mg to about 300 mgper dose, or about 50 mg to about 250 mg per dose, or about 75 mg toabout 150 mg per dose. The amount of CBD can be at least 5 mg, 7.5 mg,10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 50 mg, 60 mg, 75 mg, or100 mg (lower values) and up to 750 mg, 500 mg, 450 mg, 400 mg, 350 mg,300 mg, 250 mg, 200 mg, 175 mg, 150 mg, 120 mg, or 100 mg (upper values)of CBD per dose, and a ranges bounded by a lower and upper value.

It turns out there are different strains of Cannabis which includediffering amounts and/or ratios of the various cannabinoid compounds.For example, Cannabis sativa typically has a relatively high THC/CBDratio. Conversely, Cannabis indica has a relative low THC/CBD ratiocompared to Cannabis sativa (although the absolute amount of THC can behigher in Cannabis indica than in Cannabis sativa). There are alsoseveral hybrid varieties or strains of Cannabis sativa and Cannabisindica that have intermediate amounts and/or ratios of cannabinoidcompounds. The amounts and/or ratios of cannabinoid compounds can changedepending on the maturity of the plant, how the plant was grown, amountof artificial or natural light, climate, nutrients, and plant partsbeing used. In general, the buds and leaves have the highest quantitiesof cannabinoid compounds, while the stems and seeds have the lowest. Inaddition, the leaves, stems and seeds can have lower THC/CBD ratio thanthe buds of the same plant.

According to several embodiments, a single strain or variety of Cannabiscan be used as the source of cannabinoid compounds in a givenpharmaceutical preparation. By way of example, amplifying preparationscan be made by extracting cannabinoid compounds from Cannabis sativa orhybrids of Cannabis sativa and Cannabis indica which are dominant towardCannabis sativa. Conversely, stabilizing preparations can be made byextracting cannabinoid compounds from Cannabis indica or hybrids ofCannabis sativa and Cannabis indica which are more dominant towardCannabis indica. Balanced preparations can be made by extractingcannabinoid compounds from hybrids of Cannabis sativa and Cannabisindica which are more balanced between THC and CBD (i.e., there is lessdominance of one over the other as compared to hybrids used to makeeither amplifying or stabilizing preparations).

According to other embodiments, multiple strains or varieties ofCannabis can be used as sources of the cannabinoid compounds in a givenpharmaceutical preparation. By way of example, amplifying preparationscan be made by extracting cannabinoid compounds from both Cannabissativa and Cannabis indica, wherein the quantity of Cannabis sativa issubstantially higher. Alternatively, amplifying preparations can be madeby extracting cannabinoid compounds from Cannabis sativa and one or morehybrids of Cannabis sativa and Cannabis indica, such as those which aredominant toward Cannabis sativa. Amplifying preparations may containplant-derived and/or synthetic THC and/or CBD.

Similarly, stabilizing preparations can be made by extractingcannabinoid compounds from both Cannabis sativa and Cannabis indica,wherein the quantity of Cannabis indica is higher. Alternatively,amplifying preparations can be made by extracting cannabinoid compoundsfrom Cannabis indica and one or more hybrids of Cannabis sativa andCannabis indica, such as those which are dominant toward Cannabisindica. In addition, leaves, stems and seeds of Cannabis sativa cannaturally have a lower THC/CBD than buds of the same plant. Amplifyingpreparations may contain plant-derived and/or synthetic CBD and/or THC.

Balanced preparations can be made by extracting cannabinoid compoundsfrom both Cannabis sativa and Cannabis indica, wherein the quantities ofCannabis indica and Cannabis indica are similar. Alternatively, balancedpreparations can be made by extracting cannabinoid compounds fromhybrids of Cannabis sativa and Cannabis indica, such as one or more thatis dominant toward Cannabis sativa and one or more that is dominanttoward Cannabis indica. Balanced preparations may contain plant-derivedand/or synthetic CBD and/or THC.

Examples of Cannabis sativa dominant strains include Santa Maria, AK-47,Malawi gold, Bazooka, Durban Poison, Maui Waui, Early Bud, Early Pearl,Early Skunk Plant, Great White Shark, Green Spirit, Haze, Haze Skunk,Hempstar, Jack Herer, Kali Mist, Ice, LamsBread x Skunk, Leda Uno,Malawi gold, Niagra x Shiva, Night Queen, Northern Lights x Haze, PowerPlant, Purple Haze, Purple Skunk, Smokey Bear, Silver Haze, Shaman,Strawberry Cough, Sweet Island Skunk, Super Silver Haze, Swazi x Skunk,Thai, Voodoo, and White Cloud.

Examples of Cannabis indica dominant strains include Afghani#1, AmstelGold, Bella Caio, Big Bud, Black Domina, Black African, Black Jack,Chitral, Celtic Cross, Celtic Stone, Chronic, DoubleGum, Early Girl,Early Skunk, Eclipse, Euforia, Green Spirit, G-13, Granddaddy Purple,Hawaiian Skunk, Hindu Kush, Holland's Hope, Hypno, HashPlant, JackFlash, K2, Lemon Stinky, Mango, Master Kush, Mazar, Mighty Might,Niagra, Northern Lights, Romulan, Pink Indica, Purple High, PurpleUrkel, Purple Star, Ruderalis Indica, Shiva, Sour Bubble, SouthernAfghani, Super Chrystal, and Twilight.

Examples of more balanced sativa-indica hybrid strains include Blueberrykush, Rainbow Kashmiri, Blue Velvet, Blueberry, BubbleBerry, Bubblegum,Buddha Plant, Cali Orange Plant, Durban Poison x Mighty Might, Flo,First Mature, Fourway#1, Fruity Pebbles, Full Moon, Jamaican Pearl,Juicy Fruit, GrapeFruit Haze, Himalayan Gold, Island Lady, KC-33, Keralax Skunk, Kushage, Northern Berry, NYC Diesel, Purple#1, Purple Kush,Romberry, Shiva Shanti, Skunk Red Hair, Skunk Passion, Skunk Haze, SwissMiss, Turtle Power, and White Widow.

The cannabinoid compounds can be extracted from one or more Cannabisplants using known methods, including organic solvent extraction, waterextraction using hot or boiling water, mixed solvents using both anorganic solvent and water, heat vaporization, fractional distillation,and the like. Depending on the method of extraction, the identifiesand/or ratios of cannabinoid compounds can be altered or selected asdesired. In general, extraction is able to provide a betterapproximation of the actual ratios of cannabinoid compounds found in aparticular Cannabis plant as compared to combustion (i.e., smoking).Combustion causes significant destruction of some of the cannabinoidcompounds and can change the THC/CBD ratio.

According to several embodiments, the at least one compound thatenhances sexual response (“response-enhancing component”) includes oneor more compounds that enhance blood flow to the genital region.Examples of response-enhancing components include compounds that dilateblood vessels, such as compounds that increase the amount of nitricoxide (NO) in the blood. These include known pharmaceutical drugs aswell as herbal supplements that have been shown to enhance sexualresponse and improve performance. The response-enhancing component canaddress ED in men and/or physical problems in women that can inhibit ordelay performance, whether from a physical or psychological standpoint.

Specific examples of response-enhancing components include sildenafil(Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®), which arepharmaceuticals known as phosphodiesterase type 5 (PDE5) inhibitors, andtheir precursors and metabolites. Compositions within the scope of theinvention may include a pharmaceutically acceptable dose of one or moreof the foregoing. A pharmaceutically acceptable dose may depend on thegender, weight and/or age of the recipient and will be within knownguidelines for these well-known compounds.

Herbal supplements can also increase NO levels in the blood to enhancesexual response and improve performance. They include at least 500 mg, 1g, 1.5 g, 2 g, 2.5 g, 3 g, 4 g, 5 g, or 6 g and up to 20 g, 15 g, 12 g,10 g, 9 g, or 8 g, or any range between lower and upper values of:L-arginine, L-citrulline, yohimbe root, ginseng (e.g., Korean redginsing), Ginkgo biloba, horny goat weed, goosefoot, Chenopodiumambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garliccombined with vitamin C, and/or damiana. Compositions within the scopeof the invention may include a pharmaceutically acceptable dose (or dosethat is effective to raise blood NO levels) of one or more of theforegoing in order to enhance sexual response and improve performance. Apharmaceutically acceptable (or effective) dose may depend on thegender, weight and/or age of the recipient and will be within knownguidelines for these compounds and compositions.

Others herbal supplemental are sold under various tradenames and includeZytenz, Vydexafil, Oxysurge, Testosyn, KOR Test Booster, Virility Ex,Natural Gain Plus, ExtenZe, Alpha T1, Happy Endings, Libido Boost Plus,Virectin, Male Extra, Climadex, Vendexafil Ultra, TestoRev, Magnum PumpXR, VigRX Plus, Ageless Male, Nugenix, Vigorplex®, Libidus, Maxidus,Xzen)(Press, Xzen Gold, Xzen Platinum, Xzen 1200, Vydexafil, AI SportsPerform, VitalKoR, Athletic Edge APE, Axcite Magnum, VirMax, VirilisPro, Virility-X, XZone, Reload, Mojo Risen, Zoom-Zooma-Zoom, Love Rider,Ninja Mojo, Mojo Nights, EreXite, VMaxx Rx, Firminite, ZenMaxx, BlackAnt, RigiRx Plus, France T253, ViaXtreme, Man Up, Herbal Vigor QuickFix, Miraculous Evil Root, Zhen Gong Fu, GoldReallas, Liu Bian Li, MV5Days, S.W.A.G., Weekend Warrior, Bali Mojo, Vimax, Tiger King, AlphaMale, Vitalikor Fast Acting, MVP Mega, MaxTreme Zen, Vicerex, Affirm XL,Kaboom Action Strips, and X-Rock. Compositions within the scope of theinvention may include a pharmaceutically acceptable dose (or dose thatis effective to raise blood NO levels) of one or more of the foregoingin order to enhance sexual response and improve performance. Apharmaceutically acceptable (or effective) dose may depend on thegender, weight and/or age of the recipient and will be within knownguidelines for these compounds and compositions.

The amount of the foregoing compounds or compositions can vary dependingon the potency and mode of action. In general, such compounds orcompositions enable men to achieve and maintain an erection byincreasing blood flow to the genital region, such as by causing the bodyto produce nitric oxide. For reasons that may not be well-understood,they also aid women when combined with one or more cannabinoid compoundsas disclosed herein, which is surprising and unexpected since theytypically have no effect on women when used alone.

While enabling sexual activity can, by itself, increase sexual pleasure,response-enhancing components do not enhance sexual pleasure per se(e.g., in a perfectly healthy man who does not suffer from erectiledysfunction, the use of response-enhancing drugs may not significantlyaffect the pleasure of the sexual act, including climax). They maysimply provide the fun and novelty of longer-lasting and/or quickerthreshold erections. Similarly, while cannabinoids can make a person“high” and therefore more relaxed and uninhibited, they are also knownto diminish sexual response and performance, particularly in men. Insome cases, they can prevent achieving or maintaining an erection. Inother cases, they can unnecessarily prolong or prevent climax.Unexpectedly, however, it has now been found that combining one or moreresponse-enhancing components with one or more pleasure-enhancingcomponents optimizes the beneficial effects of both while offsetting oreliminating the negative effects. This greatly enhances the overallsexual experience.

Even more unexpectedly, combining one or more response-enhancingcomponents with one or more pleasure-enhancing components can providethe elusive aphrodisiac (or “Spanish fly”) that has been the subject ofmyth and lore but not actually achieved in reality. Unlike men, in whichsexual activity is predominately (and logistically) physical andsecondarily psychological, women can technically engage in sexualactivity whether or not they care to or are aroused. As such, sexualpleasure is more complicated in women and is as much or morepsychological as it is physical. For this reason, in both humans andanimals, sexual activity is typically initiated by males rather thanfemales. The pharmaceutical preparations disclosed herein can shift thisbalance and give women more initial threshold desire as well as actualsexual pleasure, which inure to the benefit of both women and theirsexual partners. Without being bound to any particular theory, it ispostulated that increasing blood flow to the genital region of women,while not itself having been proven to increase sexual pleasure orsexual response, increases the effects of the cannabinoid compounds,both physically and psychologically so that, when used together, theysynergistically act together to provide increased sexual pleasure andresponse as compared to when using either alone.

The pharmaceutical preparations can have a variety of different modes ofdelivery, which can be gender-specific or otherwise tailored for thespecific needs or desires of the patient. According to an embodiment,the pharmaceutical preparation can be designed as a topical (external orinternal, including body cavity, but excluding oral and nasal), e.g.,massage oils, lotions, gels, creams, lubricants, genital sprays, vaginalpatch, vaginal suppository, or anal suppository. Alternatively or inaddition, they can be formulated for ingestion, e.g., capsules, tablets,oral drops, lozenges, lollipops, and food preparations, i.e., “edibles”(aka ingestible, in contrast to sublingual or buccal absorption), suchas brownies, cookies, chocolates, chews, gum drops, soft candies, hardcandies, liquid shots, and the like). Alternatively, they can beformulated for inhalation into the lungs (e.g., by a heat vaporizer(“vape”) or nebulizer).

Capsules include any delivery form that includes an outer coveringenclosing the actives. The outer covering can be any suitable materialknown in the art, such as gelatin, starch, cellulose ether, gum,protein, or polysaccharide. Tablets include actives compressed into asolid form, sometimes with a binder or inert component. While manycapsules and tablets are configured to be swallowed whole, they may alsobe divided into pieces and swallowed, in some cases chewed andswallowed, sometimes crushed by the teeth to release a liquid, gel orsolid that is swallowed. Some tablets or capsules can be used vaginallyor anally as suppositories. Or they may be used buccally orsublingually.

A “solid ingestible” includes dosage forms that can be swallowed with noor minimal chewing (e.g., some types of capsules and tablets); dosageforms that are chewed and swallowed, such as food preparations and otheredibles (e.g., brownies, cookies, desserts, chocolates, chews, gumdrops, soft candies, and some types of capsules and tablets); dosageforms that dissolve in the mouth and are swallowed (e.g., hard candies,lollipops, lozenges, some types of capsules and tablets). Acharacteristic of a solid ingestible is that the active is intended tobe absorbed in the stomach, gut and/or small intestine, as opposed tobeing primarily absorbed buccally or sublingually.

A “liquid ingestible” includes a liquid or gel that can be swallowedwith little or no chewing. A characteristic of a solid ingestible isthat the active is intended to be absorbed in the stomach, gut and/orsmall intestine, as opposed to being primarily absorbed buccally orsublingually. A liquid ingestible can be a shot, a drink, gel pack, oraldrops, and the like.

“Dual delivery” compositions can be applied and absorbed in more thanone way. Examples include flavored body oils, creams, lotions, liquids,gels, and lubricants, which can be placed on areas of the body wherethey can be readily absorbed, such as on the skin, especially on or inthe genital region, anal region, or armpits of a man or woman, andoptionally licked or ingested by the other partner during applicationand sex play. In some cases, a composition can be placed on or in thegenital (or anal) region of one partner and transferred to the genital(or anal) region of the other partner during sex play and intercourse.Such compositions can be placed on or in sex toys, vibrators, dildos,condoms, other prophylactic devices, props, and the like.

In general, extraction of cannabinoids and then delivery withoutcombustion provides superior results compared to smoking weed andingesting an ED drug. Combustion destroys a significant quantity ofcannabinoid compounds and can change their ratios, which makes properdosing difficult. Smoking weed and ingesting an ED drug also suffersfrom the inability to control the timing of each, since smoking causesalmost instantaneous high while ingesting an ED drug takes time for thebody to metabolize. The result can be premature cannabinoid effect, withdelayed blood-flow increasing effect coupled with reduced cannabinoideffect when it is desirable for both to be maximized. Delivering boththe pleasure-enhancing and performance-enhancing components in a singlepreparation and/or in the same manner can better control dosing andtiming.

Where it is desired to inhale a cannabinoid infused material, such as aliquid, gel or paste, vaporizing apparatus known in the art fordelivering nicotine can be used. The concentration of cannabinoids inthe vape juice or oil can be adjusted, similar to how it is done whendelivering nicotine using a vape stick, hookah, or mod box, so that apredetermined number of puffs will deliver a predetermined amount of theone or more cannabinoids of interest.

Nebulizers known in the art used in hospitals, for hospice or for homecare can be used to deliver a predetermined amount of cannabinoids.

In addition to the cannabinoids, the other active for increasing bloodflow can be delivered by any suitable means to provide a predeterminedquantity of the active. These include oral ingestion, topical delivery,and inhalation, although oral ingestion by capsule or table is currentlythe most prescribed delivery method.

EXAMPLES

For purposes of the following examples, sexual pleasure and sexualresponse are assigned a value on a scale of 1 to 10, with 1 being thelowest and 10 being the highest. Three categories in men were measured:hardness of erection on a scale of 1 to 10; sensitivity on a scale of 1to 10; and strength of orgasm on a scale of 1 to 10. Three categories inwomen are measured: threshold desire on a scale of 1 to 10; sensitivityon a scale of 1 to 10; and strength of orgasm on a scale of 1 to 10.

Example 1A

The subject was a 41 year old male. The marijuana strain used to providethe cannabinoid compounds was AK-47 hybrid strain. The cannabinoidcompounds from marijuana were delivered orally usable an edible.Marijuana plant parts (mostly leaves and buds) were ground up andsimmered in vegetable oil for 3 hours to extract cannabinoid compounds(primarily THC and CBD) and then strained. The cannabinoid infused oilwas assumed to contain roughly the same ratio of THC to CBD in the plantparts (as well as other cannabinoids in the plant parts). The minorcannabinoids did not negate or substantially alter the predominatingeffects of the THC and CBD.

The infused oil was used in place of the oil called for in normalpreparation of brownies per instructions. The cannabinoid infused oilwas blended in an amount of ¼ ounce per 18 ounce fudge brownie mix.Brownies containing the extracted cannabinoid compounds were preparedfrom the mixed batter by placing into a small cake pan (6 in²) and bakedin the over according to instructions. A small pan of brownies was cutup into 3 inch squares.

The subject ingested two brownies and one XZEN pill. [Note: it was laterdiscovered that XZEN used in this and other examples herein may havebeen tainted with a pharmaceutical, such as sildenafil, tadalafil, orvardenafil, or biosimilar compound, because it was pulled from themarket and modified.] The subject started noticing the effects of bothafter about 1 hour and commenced sexual activity with a female partnershortly thereafter. The subject was able to obtain and maintain a harderection and sensitivity and pleasure during sex were increased. Thesubject was able to last longer than usual and, in this case, sex lastedabout 30 minutes. At the culmination, ejaculation was very intense. Thestatistics were (on a scale of 1 to 10): hardness of erection: 9;sensitivity: 8; strength of orgasm: 10.

Example 1B

The female partner in Example 1A weighed less than the male subject inExample 1A and ingested one cannabinoid infused brownie square and alsoexperienced heightened sensitivity (8) and pleasure during the sexualactivity, which was attributed to reduced anxiety and inhibition andincreased threshold desire. The female did not ingest any blood flowenhancements. It is postulated that the female partner would furtherbenefit from combining ingestion of the cannabinoid edible with acomponent that increases blood flow to the female genital region inorder to increase threshold desire (e.g., 8 as a result of swelling andthickening of the clitoris and labia), as well as more intense orgasm(e.g., 8) as a result of the combined psychological and physiologicaleffects of ingesting both the pleasure-enhancing andperformance-enhancing component.

Example 1C

The female partner ingests the cannabinoid edible with a component thatincreases blood flow to the female genital region. The combinationincreases threshold desire (e.g., 8 as a result of swelling andthickening of the clitoris and labia), as well as more intense orgasm(e.g., 8) as a result of the combined psychological and physiologicaleffects of ingesting both the pleasure-enhancing andperformance-enhancing component.

Example 2A

The subject was a 70 year old male. The marijuana strain used to providethe cannabinoid compounds was AK-47. The cannabinoid compounds wereextracted by simmering ¼ ounce of marijuana in 1 cup avocado oil to makebutter. The subject spread approximately 1 tablespoon of the butter ontotoast and then ingested the toast and one XZEN pill on an empty stomach.After 45 minutes the subject felt some flushing and effects of thecannabinoid compounds.

After one hour the subject had a hard erection and proceeded to have sexwith a female partner of similar age. The sex lasted an amazing 2 hoursand the subject was able to ejaculate 5 times within that time span,which would be remarkable for a young man, but in this case the subjectwas a 70 year old man. The statistics were (on a scale of 1 to 10):hardness of erection: 10; sensitivity: 9; strength of orgasm: 9. Thisexample exemplifies the benefit to an older man of using cannabinoidswith a higher ratio of THC:CBD (at least 2:1). The subject's opinion wasthat the sex was like being a young man all over again (“21 again”), andhis overall mood in general improved dramatically (demeanor anddisposition), which was another unexpected benefit.

The female partner in Example 2A did not ingest any enhancements.However, it is postulated that the female partner would benefit fromingesting the preparations disclosed herein and experience increasedthreshold desire (8), heightened sensitivity and pleasure (8), and morepowerful orgasm (8).

Example 2B

This example is repeated but with the man ingesting Viagra® instead ofXZEN with similar results. The example is modified by substitutingViagra® or XZEN with any other known male enhancement, such as Cialis®,Levitra®, L-arginine, horny goat weed, and the like.

Example 3A

The subject was a 41 year old male. The marijuana strain used to providethe cannabinoid compounds was Blueberry Kush. The cannabinoid compoundswere delivered orally using an edible. The marijuana plant parts (mostlyleaves and buds) were ground up and simmered in vegetable oil for 3hours to extract cannabinoid compounds and then strained. Thecannabinoid infused oil was assumed to contain roughly the same ratio ofTHC to CBD in the plant parts (as well as other cannabinoids in theplant parts). The minor cannabinoids did not negate or substantiallyalter the predominating effects of the THC and CBD.

The infused oil was used in place of the oil called for in normalpreparation of brownies per instructions. The cannabinoid infused oilwas blended in an amount of ¼ ounce per 18 ounce fudge brownie mix.Brownies containing the extracted cannabinoid compounds were preparedfrom the mixed batter by placing into a small cake pan (6 in²) and bakedin the over according to instructions. A small pan of brownies was cutup into 3 inch squares.

The subject ingested two brownies and one XZen pill. The subject startednoticing the effects of both after about 1 hour and commenced sexualactivity shortly thereafter. The subject was able to maintain a harderection and sensitivity was increased. The subject was able to lastlonger and sex lasted about 45 minutes with a female partner.Ejaculation was very intense. The subject was thereafter able to achieveanother erection after 30 minutes and commenced sexual activity again,which lasted about 30 minutes, and able to achieve a second orgasm. Thestatistics were (on a scale of 1 to 10): hardness of erection: 9;sensitivity: 8; strength of orgasm: 9. This example, as compared toExamples 1 and 2, demonstrates the beneficial effects for a relativelyyoung, healthy man when using a cannabinoid having a more balanced ratioof THC to CBD (which was closer to 1:1 than in Example 1 and possiblyless 1:1), relative to the ability to last longer.

Example 3B

The female partner in Example 3A ingested one cannabinoid infusedbrownie square and also experienced heightened sensitivity and pleasure(8) during the sexual activity, which was attributed to reduced anxietyand inhibition and increased threshold desire. The female did not ingestany blood flow enhancements. It is postulated that the female partnerwould further benefit from combining ingestion of the cannabinoid ediblewith a component that increases blood flow to the female genital regionin order to increase threshold desire (e.g., 8 as a result of swellingand thickening of the clitoris and labia), as well as more intenseorgasm (8) as a result of the combined psychological and physiologicaleffects of ingesting both the pleasure-enhancing andperformance-enhancing component.

Example 4A

The subject was a 70 year old male. The marijuana strain used to providethe cannabinoid compounds was Blueberry Kush. The cannabinoid compoundswere extracted by simmering ¼ ounce of marijuana in 1 cup avocado oil tomake butter. The subject spread approximately 1 tablespoon of the butteronto toast and then ingested the toast and one XZEN pill on an emptystomach. After 45 minutes the subject felt some flushing and effects ofthe cannabinoid compounds.

After one hour the subject had a hard erection and proceeded to have sexwith a female partner of similar age. The sex lasted 2 hours and thesubject was able to ejaculate 3 times within that time span. Thestatistics were (on a scale of 1 to 10): hardness of erection: 10;sensitivity: 9; strength of orgasm: 9. This example demonstrated thatwhile a clear benefit was obtained by the subject ingesting a balancedratio of THC:CBD, the results were not quite as dramatic as Example 2,in which the subject ingested a higher ratio of THC:CBD and was able toachieve 5 orgasms instead of 3.

The female partner did not ingest any enhancements. However, it ispostulated that the female partner would benefit from ingesting thepreparations disclosed herein and experience increased threshold desire(8), heightened sensitivity and pleasure (8), and more powerful orgasm(8).

Example 5

A 50 year old male ingested a single brownie prepared according toExample 3 and one XZen pill. The subject felt the effects of bothcomponents and was able to achieve an erection more quickly and maintainit longer. The subject engaged in sexual activities with a femalepartner within about 1-2 hours of ingestion lasting about 30 minutes.The subject had an erection of about an 8, heightened sensitivity ofabout 8; and a more intense orgasm of about 8. It is postulated that themale subject might have benefited more using the higher THC:CBDpreparation and/or ingesting an increased quantity of the edible.

The female partner did not ingest any enhancements. However, it ispostulated that the female partner would benefit from ingesting thepreparations disclosed herein and experience increased threshold desire(8), heightened sensitivity and pleasure (8), and more powerful orgasm(8).

Example 6

The subject is a 22 year old male who is provided with an infused ediblemade according to any of the foregoing Examples. The subject is strongand virile but prone to premature ejaculation. The subject ingests theinfused edible together with a component that increases blood flow tothe genital region (e.g., XZen or part of a Viagra®). After 20-30minutes the subject has a hard erection and proceeds to have sex with apartner. When using an edible with high THC:CBD ratio, the sex is brief(about 1-3 minutes) but intense. The statistics are (on a scale of 1 to10): hardness of erection: 10; sensitivity: 8; strength of orgasm: 8.

Alternatively, the subject ingests a cannabinoid infused edible having ahigher ratio of CBD:THC and experiences the same quality of erection,sensitivity, and strength of orgasm but is able to last much longer thanusual (e.g., 15-45 minutes), which greatly boosts the subject'sconfidence when engaging in sexual activities with others. Due to thesubject's age, he is able to achieve multiple orgasms with fast orimmediate recovery between ejaculations.

This example demonstrates that, while a clear benefit is obtained by thesubject ingesting a high ratio of THC:CBD, the results are objectivelymuch better when the subject ingests a much lower ratio of THC:CBD (orhigher ratio of CBD:THC). It is postulated that a more balanced ratio ofTHC:CBD would provide an intermediate benefit between the extremesdescribed herein.

Example 7

The subject is a 21 year old female who is provided with an infusededible made according to any of the foregoing Examples. The subject ishealthy but inexperienced and nervous when engaging in sexual activity,which decreases threshold desire, pleasure and fulfillment, and makes itdifficult or impossible for the subject to achieve orgasm. The subjectingests the infused edible together with a component that increasesblood flow to the genital region (e.g., XZen for Women or part of aViagra®). After about 1 hour the subject feels flushing and the effectsof the cannabinoid compounds and the blood flow enhancer, includingincreased swelling of the vulva and nipples which, although largelyphysiological, combine with the enhanced psychological effects ofexcitement and decreased anxiety provided by the infused edible toincrease threshold desire (e.g., 9).

When the subject ingests an edible containing a high THC:CBD ratio, thesubject may be more physically aggressive but might still havedifficulty achieving orgasm regularly. It is postulated that a higherCBD:THC ratio would provide a calming effect that permits deeperpsychological appreciation and enjoyment of sexual activity, leading tomore reliable and fulfilling orgasms. Depending on the woman, anintermediate TCD:CBD ratio may be sufficiently calming, yet moreexcitatory so as to promote quicker and/or multiple orgasms.

Example 8

A 25 year old female subject is provided with an infused edible madeaccording to any of the foregoing Examples. The subject ingests theinfused edible together with a component that increases blood flow tothe genital region (e.g., XZen for Women or part of a Viagra®). Afterabout 1 hour the subject feels flushing and the effects of thecannabinoid compounds, including increased swelling of the vulva andnipples which, although largely physiological, combine with the enhancedpsychological effects of excitement and decreased anxiety provided bythe infused edible to increase threshold desire.

After one hour the subject commences sexual activity with a 41 year oldmale partner. The subject experiences heightened sensitivity (9) andpleasure and is able to climax more quickly and more powerfully (9) thanusual. Depending on the endurance of her male sex partner, the femalesubject is able to achieve multiple orgasms as a result of the increasedphysiological and psychological awareness and sensitivities provided bythe combined use of pleasure-enhancing and performance-enhancingcomponents. Because of the female subject's age (25) and sexualconfidence, it is postulated that the subject would, like the 41 yearold subject of Examples 1 and 3, benefit from an edible having abalanced THC:CBD ratio.

Example 9

A 68 year old female subject of normal sexual experience and activityfor her age is provided with an infused edible made according to any ofthe foregoing Examples. The subject ingests the infused edible togetherwith a component that increases blood flow to the genital region (e.g.,XZen for Women or part of a Viagra®). After about 1 hour the subjectfeels flushing and the effects of the cannabinoid compounds and bloodflow enhancer, including increased swelling of the vulva and nippleswhich, although largely physiological, combine with the enhancedpsychological effects of excitement and decreased anxiety provided bythe infused edible to increase threshold desire.

After one hour the subject commences sexual activity with a male partnerof similar age. The subject experiences high threshold desire (7),heightened sensitivity (9) and is able to climax more quickly and morepowerfully (9) than usual. Depending on the endurance of her male sexpartner, the female subject is able to achieve multiple orgasms as aresult of the increased physiological and psychological awareness andsensitivities provided by the combined use of pleasure-enhancing andperformance-enhancing components. Because of the female subject's age(68), it is postulated that the subject would, like the 70 year oldsubject of Examples 2 and 4, benefit more from an edible having a higherTHC:CBD ratio.

Example 10

A 45 year old female subject is provided with an infused edible madeaccording to any of the foregoing Examples. The subject ingests theinfused edible together with a component that increases blood flow tothe genital region (e.g., XZen for Women or part of a Viagra®). Afterabout 1 hour the subject feels flushing and the effects of thecannabinoid compounds and blood flow enhancer, including increasedswelling of the vulva and nipples which, although largely physiological,combine with the enhanced psychological effects of excitement anddecreased anxiety provided by the infused edible to increase thresholddesire (9).

After one hour the subject commences sexual activity with a male partnerof similar age. The subject experiences heightened sensitivity (9) andpleasure and is able to climax more quickly and more powerfully (9) thanusual. Depending on the endurance of her male sex partner, the femalesubject is able to achieve multiple orgasms as a result of the increasedphysiological and psychological awareness and sensitivities provided bythe combined use of pleasure-enhancing and performance-enhancingcomponents. Because of the female subject's age (45), it is postulatedthat the subject would, like the 50 year old subject of Example 5,benefit more from an edible having a higher THC:CBD ratio and/oringesting a higher quantity of edible having a balanced THC:CBD ratio.

Example 11

A 70 year old female subject who rarely engages in sexual activitybecause of lost desire and pleasure is provided with an infused ediblemade according to any of the foregoing Examples. The subject ingests theinfused edible together with a component that increases blood flow tothe genital region (e.g., XZen for Women or part of a Viagra®). Afterabout 1 hour the subject feels flushing and the effects of thecannabinoid compounds and blood flow enhancer, including increasedswelling of the vulva and nipples which, although largely physiological,combine with the enhanced psychological effects of excitement anddecreased anxiety provided by the infused edible to increase thresholddesire (7 or 8).

After one hour the subject commences sexual activity with a male partnerof similar age. The subject experiences heightened sensitivity (7 or 8)and pleasure and is able to achieve climax (6 or 7), perhaps for thefirst time in a long time or ever. Depending on the endurance of hermale sex partner, the female subject is able to achieve multiple orgasmsas a result of the increased physiological and psychological awarenessand sensitivities provided by the combined use of pleasure-enhancing andperformance-enhancing components. Because of the female subject's age(70), it is postulated that the subject might, like the 70 year oldsubject of Examples 2 and 4, benefit more from an edible having a higherTHC:CBD ratio.

Example 12

Any of the foregoing examples is modified by providing at least one ofthe components (e.g., pleasure-enhancing component) in a preparationthat can delivered by inhalation. Examples include, for example,vaporizers that heat one or more components of the pharmaceuticalpreparation with water or “vape juice” (e.g., glycerin and/or propyleneglycol) to provide a vapor that carries the components of interest andcan be inhaled. The temperature and/or selection of vaporizing liquidscan affect the concentration and/or ratio of cannabinoids delivered tothe user.

Example 13

Any of the foregoing examples is modified by providing at least one ofthe components (e.g., pleasure-enhancing component) in a topicalpreparation that can be applied to any region of the body able torapidly absorb the active components. Examples include, for example, thegenital and/or anal regions of men and women.

The present invention may be embodied in other specific forms withoutdeparting from its spirit or essential characteristics. The describedembodiments are to be considered in all respects only as illustrativeand not restrictive. The scope of the invention is, therefore, indicatedby the appended claims rather than by the foregoing description. Allchanges which come within the meaning and range of equivalency of theclaims are to be embraced within their scope.

What is claimed is:
 1. A method of treating sexual dysfunction in ahuman in need thereof comprising: a) administering orally by ingestionwhich is not smoking or applying topically to said human in need thereofa therapeutically effective amount of a cannabinoid component comprisingat least one of tetrahydrocannabinol and cannabidiol; b) administeringorally by ingestion which is not smoking or applying topically to saidhuman in need thereof a therapeutically effective amount of a sexualresponse component selected from the group consisting of sildenafil,tadalafil, and vardenafil; and c) the cannabinoid component and thesexual response component effectively treating said sexual dysfunctionin said human in need thereof.
 2. The method of claim 1, wherein thecannabinoid component contains about 10-500 mg of tetrahydrocannabinol.3. The method of claim 1, wherein the cannabinoid component containsabout 10-250 mg of tetrahydrocannabinol.
 4. The method of claim 1,wherein the cannabinoid component contains about 10-500 mg ofcannabidiol.
 5. The method of claim 1, wherein the cannabinoid componentcontains about 10-250 mg of cannabidiol.
 6. The method of claim 1,wherein the cannabinoid component comprises tetrahydrocannabinol and/orcannabidiol, and at least one other cannabinoid other thantetrahydrocannabinol and cannabidiol.
 7. The method of claim 1, whereinthe cannabinoid component, when administered orally, is a dosage formselected from the group consisting of capsules, tablets, oral drops,infused edibles, infused food preparations, and brownies.
 8. The methodof claim 1, wherein the cannabinoid component, when administeredtopically, is a dosage form selected from the group consisting ofmassage oil, lotion, gel, cream, lubricant, patch, and suppository. 9.The method of claim 1, wherein the sexual response component, whenadministered orally, is a dosage form selected from the group consistingof capsules, tablets, oral drops, edibles, and infused foodpreparations.
 10. The method of claim 1, wherein the sexual responsecomponent, when administered topically, is a dosage form selected fromthe group consisting of massage oil, lotion, gel, cream, lubricant,patch, and suppository.
 11. The method of claim 1, wherein said sexualdysfunction is male sexual dysfunction selected from erectiledysfunction, low sexual desire, arousal disorder, and orgasmic disorder.12. The method of claim 1, wherein said sexual dysfunction is femalesexual dysfunction selected from low sexual desire, arousal disorder,and orgasmic disorder.
 13. A method of treating female sexualdysfunction selected from low sexual desire, arousal disorder, andorgasmic disorder in a human in need thereof comprising: a)administering orally by ingestion which is not smoking or applyingtopically to said human in need thereof a therapeutically effectiveamount of a cannabinoid component comprising at least one oftetrahydrocannabinol and cannabidiol; and b) administering orally byingestion which is not smoking or applying topically to said human inneed thereof a therapeutically effective amount of a sexual responsecomponent selected from the group consisting of sildenafil, tadalafil,vardenafil, L-arginine, yohimbe, ginseng, gingko biloba, horny goatweed, and herbal supplements that increase blood flow to the genitalregion and are not cannabinoids; and c) the cannabinoid component andthe sexual response component effectively treating said female sexualdysfunction in said human in need thereof.
 14. The method of claim 13,wherein the cannabinoid component contains about 10-250 mg oftetrahydrocannabinol and/or about 10-250 mg of cannabidiol.
 15. Themethod of claim 13, wherein: the cannabinoid component, whenadministered orally, is a dosage form selected from the group consistingof capsules, tablets, oral drops, infused edibles, infused foodpreparations, and brownies; or the cannabinoid component, whenadministered topically, is a dosage form selected from the groupconsisting of massage oil, lotion, gel, cream, lubricant, patch, andsuppository.
 16. The method of claim 13, wherein: the sexual responsecomponent, when administered orally, is a dosage form selected from thegroup consisting of capsules, tablets, oral drops, infused edibles, andinfused food preparations; or the sexual response component, whenadministered topically, is a dosage form selected from the groupconsisting of massage oil, lotion, gel, cream, lubricant, patch, andsuppository.
 17. A method of treating sexual dysfunction selected fromlow sexual desire, arousal disorder, and orgasmic disorder in a human inneed thereof comprising: a) administering orally by ingestion which isnot smoking or applying topically to said human in need thereof atherapeutically effective amount of a cannabinoid component comprisingat least one of tetrahydrocannabinol and cannabidiol; and b)administering orally by ingestion which is not smoking or applyingtopically to said human in need thereof a therapeutically effectiveamount of a sexual response component selected from the group consistingof sildenafil, tadalafil, vardenafil, L-arginine, yohimbe, ginseng,Gingko biloba, horny goat weed, and herbal supplements that increaseblood flow to the genital region and are not cannabinoids; and c) thecannabinoid component and the sexual response component effectivelytreating said sexual dysfunction in said human in need thereof.
 18. Themethod of claim 17, wherein: the cannabinoid component, whenadministered orally, is a dosage form selected from the group consistingof capsules, tablets, oral drops, infused edibles, infused foodpreparations, and brownies; or the cannabinoid component, whenadministered topically, is a dosage form selected from the groupconsisting of massage oil, lotion, gel, cream, lubricant, patch, andsuppository.
 19. The method of claim 17, wherein: the sexual responsecomponent, when administered orally, is a dosage form selected from thegroup consisting of capsules, tablets, oral drops, edibles, and infusedfood preparations; or the sexual response component, when administeredtopically, is a dosage form selected from the group consisting ofmassage oil, lotion, gel, cream, lubricant, patch, and suppository. 20.The method of claim 17, wherein the sexual response component isselected from the group consisting of L-arginine, yohimbe, ginseng,Gingko biloba, horny goat weed, and herbal supplements that increaseblood flow to the genital region and are not cannabinoids.
 21. Themethod of claim 20, wherein the sexual response component is selectedfrom the group consisting of L-arginine, yohimbe, ginseng, gingkobiloba, and horny goat weed.